Log in

Voyager Therapeutics Stock Price, Forecast & Analysis (NASDAQ:VYGR)

$14.51
+0.98 (+7.24 %)
(As of 11/21/2019 08:00 AM ET)
Today's Range
$13.39
Now: $14.51
$14.73
50-Day Range
$12.68
MA: $15.06
$16.97
52-Week Range
$7.76
Now: $14.51
$28.79
Volume726,400 shs
Average Volume448,366 shs
Market Capitalization$537.93 million
P/E RatioN/A
Dividend YieldN/A
Beta2.58
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD101 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and VY-NAV01 for severe chronic pain. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VYGR
CUSIPN/A
Phone857-259-5340

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.62 million
Book Value$1.43 per share

Profitability

Net Income$-88,290,000.00

Miscellaneous

Employees123
Market Cap$537.93 million
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive VYGR News and Ratings via Email

Sign-up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter.


Voyager Therapeutics (NASDAQ:VYGR) Frequently Asked Questions

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics Inc (NASDAQ:VYGR) released its earnings results on Wednesday, November, 6th. The company reported ($0.41) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.83) by $0.42. The firm earned $20.43 million during the quarter, compared to analysts' expectations of $3.94 million. Voyager Therapeutics had a negative net margin of 72.64% and a negative return on equity of 57.32%. View Voyager Therapeutics' Earnings History.

When is Voyager Therapeutics' next earnings date?

Voyager Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Voyager Therapeutics.

What price target have analysts set for VYGR?

8 brokers have issued 12 month price targets for Voyager Therapeutics' shares. Their forecasts range from $23.00 to $37.00. On average, they anticipate Voyager Therapeutics' stock price to reach $29.17 in the next year. This suggests a possible upside of 101.0% from the stock's current price. View Analyst Price Targets for Voyager Therapeutics.

What is the consensus analysts' recommendation for Voyager Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Voyager Therapeutics.

What are Wall Street analysts saying about Voyager Therapeutics stock?

Here are some recent quotes from research analysts about Voyager Therapeutics stock:
  • 1. According to Zacks Investment Research, "Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (11/9/2019)
  • 2. Nomura analysts commented, "Minor Tweaks Post-NBIX Collab., Revising Patient Numbers and Statistical Plan; No Data Guidance Yet. The first pivotal Parkinson’s disease trial, RESTORE-1, is undergoing minor modifications now that VYGR is partnered with NBIX. VYGR had previously guided to a 75-100 patient trial, but this is likely going to be clarified as the statistical analysis plan is finalized. No data guidance yet—but we expect an update when the target enrollment is finalized and when VYGR gets a sense of the pace of enrollment. Huntington’s Program IND by YE19 – Finalizing Clinical Team and Planning to Use Commercial-Grade Gene Therapy Material. Voyager recently attained full rights after the SNY collaboration restructuring (see our note here). VYGR plans to have an IND by YE19 and will use material that is “very, very similar” to commercial material to avoid any step back in the future." (8/13/2019)
  • 3. HC Wainwright analysts commented, "Our current target is based on a 12-year DCF analysis primarily focused on VY-AADC in PD. Our DCF analysis is based on: beta of 1.62, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2030." (8/12/2019)

Has Voyager Therapeutics been receiving favorable news coverage?

Media coverage about VYGR stock has been trending positive recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Voyager Therapeutics earned a news sentiment score of 3.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Voyager Therapeutics.

Who are some of Voyager Therapeutics' key competitors?

What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include TFI International (TFII), Micron Technology (MU), TG Therapeutics (TGTX), Editas Medicine (EDIT), Exelixis (EXEL), Fate Therapeutics (FATE), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE) and Applied Optoelectronics (AAOI).

Who are Voyager Therapeutics' key executives?

Voyager Therapeutics' management team includes the folowing people:
  • Mr. Matthew P. Ottmer, Chief Operating Officer (Age 48)
  • Dr. Steven M. Paul, Exec. Science Advisor & Director (Age 68)
  • Mr. G. Andre Turenne, CEO, Pres & Director
  • Dr. Krystof Bankiewicz M.D., Ph.D., Founder
  • Dr. Guangping Gao Ph.D., Founder

Who are Voyager Therapeutics' major shareholders?

Voyager Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Bailard Inc. (0.32%), Alps Advisors Inc. (0.20%), Strs Ohio (0.10%), Tocqueville Asset Management L.P. (0.08%), Chicago Equity Partners LLC (0.06%) and Patriot Financial Group Insurance Agency LLC (0.06%). Company insiders that own Voyager Therapeutics stock include Bernard Ravina, Dinah PhD Sah, Glenn Pierce, James A Geraghty, Jane Henderson and Neurocrine Biosciences Inc. View Institutional Ownership Trends for Voyager Therapeutics.

Which institutional investors are selling Voyager Therapeutics stock?

VYGR stock was sold by a variety of institutional investors in the last quarter, including Patriot Financial Group Insurance Agency LLC, Alps Advisors Inc. and Meeder Asset Management Inc.. View Insider Buying and Selling for Voyager Therapeutics.

Which institutional investors are buying Voyager Therapeutics stock?

VYGR stock was purchased by a variety of institutional investors in the last quarter, including Bailard Inc., Chicago Equity Partners LLC, Strs Ohio, First Quadrant L P CA, Russell Investments Group Ltd., Tocqueville Asset Management L.P., California Public Employees Retirement System and Convergence Investment Partners LLC. Company insiders that have bought Voyager Therapeutics stock in the last two years include Glenn Pierce, James A Geraghty and Neurocrine Biosciences Inc. View Insider Buying and Selling for Voyager Therapeutics.

How do I buy shares of Voyager Therapeutics?

Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Voyager Therapeutics' stock price today?

One share of VYGR stock can currently be purchased for approximately $14.51.

How big of a company is Voyager Therapeutics?

Voyager Therapeutics has a market capitalization of $537.93 million and generates $7.62 million in revenue each year. The company earns $-88,290,000.00 in net income (profit) each year or ($2.75) on an earnings per share basis. Voyager Therapeutics employs 123 workers across the globe.View Additional Information About Voyager Therapeutics.

What is Voyager Therapeutics' official website?

The official website for Voyager Therapeutics is http://www.voyagertherapeutics.com/.

How can I contact Voyager Therapeutics?

Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-5340 or via email at [email protected]


MarketBeat Community Rating for Voyager Therapeutics (NASDAQ VYGR)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  311 (Vote Outperform)
Underperform Votes:  258 (Vote Underperform)
Total Votes:  569
MarketBeat's community ratings are surveys of what our community members think about Voyager Therapeutics and other stocks. Vote "Outperform" if you believe VYGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VYGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel